Sodium benzoate is under clinical development by SyneuRx International (Taiwan) and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sodium benzoate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sodium benzoate overview
Sodium benzoate (SND-1, SB-01, SR-01) is under development for the treatment of adolescent schizophrenia, refractory schizophrenia, add-on therapy in schizophrenia and dementia. It is administered through the oral route. It acts by targeting D-amino acid oxidase (DAAO).
SyneuRx International (Taiwan) overview
SyneuRx International (Taiwan) (SyneuRx International) is a bio-medical company that specializes in developing drugs for the treatment of central nervous system-related disorders. The company is headquartered in Taipei City, Taipei, Taiwan.
For a complete picture of Sodium benzoate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
